Abogen
Business Services · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Building B1 no.218 Xinghu Street Suzhou ...Phone Number
(207) 939-1665Website
www.abogenbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Abogen
Abogen was founded in 2012, with the goal of enabling the future of personalized medicine by developing novel alternatives to blood to obtain comprehensive genomic information.Explore more
Abogen Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Abogen your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Abogen had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Abogen
Check out if Abogen is spiking on competitors!
Abogen, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Abogen has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Abogen has new funding data
Earning: See what the market has to say on Abogen recently announced quarterly report
Product Launch: Get notified when Abogen launches new products
Recommended Actions
Reach out to Masked Content who joined Abogen as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Abogen is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Abogen is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Abogen.
Abogen financials insights
Gather financial insights about Abogen, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Multiple Rounds
$1.1B
Abogen Tech Stack
A closer look at the technologies used by Abogen
See more technologies
Most Recent Scoops
Event
Product Marketing, Events, Sales, Laboratory Operations, Pharmaceuticals, Field /Outside Sales, Clinical Operations, Field Marketing, Healthcare Operations, Operations
Open Position
Funding
Funding
Funding
Funding
Abogen News & Media
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The...AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL
SAN DIEGO, April 20, 2026 /PRNewswire/ -- Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). The...Abogen announced development of Cis-System-based circular RNAs
SUZHOU, China, Aug. 23, 2024 /PRNewswire/ -- Abogen Biosciences ("Abogen" or the "Company") announced a publication titled "Efficient circularization of protein-encoding RNAs via a novel cis-splicing system " in Nucleic Acids Research. In the article, Abogen has revealed a highly...Chinese Omicron-specific mRNA COVID vaccine candidate to be trialed in UAE
China's Suzhou Abogen Biosciences Co said its COVID-19 vaccine candidate using the messenger RNA (mRNA) technology and targeting the Omicron variant has obtained clinical trial approval in the United Arab Emirates. With Friday's announcement, Abogen joins Pfizer/BioNTech and Moderna in trialing candidates modified specifically against Omicron, a highly transmissible variant with increased resistance to antibodies elicited by existing shots. Mainland China has vaccinated over 88% of its 1.4 billi
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Abogen
Sign Up For FreeTo access detailed company insights
Abogen was founded in 2012, with the goal of enabling the future of personalized medicine by developing novel alternatives to blood to obtain comprehensive genomic information.... Read More
